The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Role of IL-1β in type 2 diabetes
Abstract
PURPOSE OF REVIEW: To understand the role of inflammation as the fundamental cause of type 2 diabetes and specifically to examine the contribution of IL-1beta. RECENT FINDINGS: Recent studies from animals, in-vitro cultures and clinical trials provide evidence that support a causative role for IL-1beta as the primary agonist in the loss of beta-cell mass in type 2 diabetes. In vitro, IL-1beta-mediated autoinflammatory process results in beta-cell death. The autoinflammation is driven by glucose, free fatty acids, leptin, and IL-1beta itself. Caspase-1 is required for IL-1beta activity and the release of free fatty acids from the adipocyte. An emerging hypothesis gains support from patients with type 2 diabetes in which an imbalance in the amount of IL-1beta agonist activity versus the specific countering by the naturally occurring IL-1 receptor antagonist (IL-1Ra) determines the outcome of islet inflammation. An important confirmation comes from clinical trials. Blockade of IL-1 receptor with anakinra, the recombinant form of IL-1Ra, or neutralizing anti-IL-1beta antibodies, provides proof-of-principle data that reducing IL-1beta activity is sufficient for correcting dysfunctional beta-cell production of insulin in type 2 diabetes, including a possibility that suppression of IL-1beta-mediated inflammation in the microenvironment of the islet allows for regeneration. SUMMARY: Monotherapy or add-on therapy targeting IL-1beta in type 2 diabetes holds promise for long-term benefits in glycemic control and possibly reducing cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Self-citationThioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationAnti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationAn Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
β-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Netea, M. G., Nold-Petry, C. A., Nold, M. F., Joosten, L. A. B., Opitz, B., van der Meer, J. H. M., van de Veerdonk, F. L., Ferwerda, G., Heinhuis, B., Devesa, I., et al. (2009) · Blood · doi:10.1182/blood-2008-03-146720 · Cited by 792
Self-citationIncreased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783
Self-citationDinarello, C. A., Ikejima, T., Warner, S. J. C., Orencole, S. F., Lonnemann, G., Cannon, J. G., & Libby, P. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.6.1902 · Cited by 537
Self-citationDeficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance
Netea, M. G., Joosten, L. A. B., Lewis, E., Jensen, D. R., Voshol, P. J., Kullberg, B. J., Tack, C. J., van Krieken, H., Kim, S.-H., Stalenhoef, A. F., et al. (2006) · Nature Medicine · doi:10.1038/nm1415 · Cited by 424
Self-citationAn Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus
Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J., & Verbsky, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809568 · Cited by 411
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
Self-citationAbbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G. L., Houser, J.-E., Qureshi, I. Z., Ownby, E. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.740233 · Cited by 360
Thioredoxin-Interacting Protein
Chen, J., Saxena, G., Mungrue, I. N., Lusis, A. J., & Shalev, A. (2008) · Diabetes · doi:10.2337/db07-0715 · Cited by 350
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
Ehses, J. A., Lacraz, G., Giroix, M.-H., Schmidlin, F., Coulaud, J., Kassis, N., Irminger, J.-C., Kergoat, M., Portha, B., Homo-Delarche, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810087106 · Cited by 347
Self-citationBöni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D. T., Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J. A., Schuit, F. C., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0543 · Cited by 339
Self-citationIncreased secretion and expression of myostatin in skeletal muscle from extremely obese women
Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., & Houmard, J. A. (2009) · Diabetes · doi:10.2337/db08-0943 · Cited by 324
Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans
Mandrup-Poulsen, T., Bendtzen, K., Nerup, J., Dinarello, C. A., Svenson, M., & Nielsen, J. H. (1986) · Diabetologia · doi:10.1007/bf02427283 · Cited by 324
Self-citationBöni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., Pattou, F., Halban, P. A., Weir, G. C., & Donath, M. Y. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0396 · Cited by 320
Self-citationIn vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Mandrup-Poulsen, T., Bendtzen, K., Dinarello, C. A., & Nerup, J. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4077 · Cited by 304
Self-citationThe global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation
Kolb, H., & Mandrup-Poulsen, T. (2010) · Diabetologia · doi:10.1007/s00125-009-1573-7 · Cited by 292
Self-citationLeptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets
Maedler, K., Sergeev, P., Ehses, J. A., Mathe, Z., Bosco, D., Berney, T., Dayer, J.-M., Reinecke, M., Halban, P. A., & Donath, M. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305683101 · Cited by 249
Self-citationGattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., D'Osualdo, A., Buoncompagni, A., Alpigiani, M. G., Alessio, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22842 · Cited by 247
Cho, Y. M., Kim, T. H., Lim, S., Choi, S. H., Shin, H. D., Lee, H. K., Park, K. S., & Jang, H. C. (2009) · Diabetologia · doi:10.1007/s00125-008-1196-4 · Cited by 243
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 237
Self-citationSchindler, R., Clark, B. D., & Dinarello, C. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86936-8 · Cited by 227
Self-citationInterleukin-1β and the Autoinflammatory Diseases
Dinarello, C. A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0811014 · Cited by 226
Self-citationShalev, A., Pise-Masison, C. A., Radonovich, M., Hoffmann, S. C., Hirshberg, B., Brady, J. N., & Harlan, D. M. (2002) · Endocrinology · doi:10.1210/en.2002-220564 · Cited by 219
Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency
Zorrilla, E. P., Sanchez-Alavez, M., Sugama, S., Brennan, M., Fernandez, R., Bartfai, T., & Conti, B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611523104 · Cited by 169
Maedler, K., Størling, J., Sturis, J., Zuellig, R. A., Spinas, G. A., Arkhammar, P. O. G., Mandrup-Poulsen, T. R., & Donath, M. Y. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1706 · Cited by 149
Self-citationMarculescu, R., Endler, G., Schillinger, M., Iordanova, N., Exner, M., Hayden, E., Huber, K., Wagner, O. F., & Mannhalter, C. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3582 · Cited by 70
Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus
Zilverschoon, G. R. C., Tack, C. J., Joosten, L. A. B., Kullberg, B. J., van der Meer, J. W. M., & Netea, M. G. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.109 · Cited by 69
Autocrine Induction of the Human Pro-IL-1β Gene Promoter by IL-1β in Monocytes
Toda, Y., Tsukada, J., Misago, M., Kominato, Y., Auron, P. E., & Tanaka, Y. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.4.1984 · Cited by 68
Lamacchia, C., Palmer, G., Seemayer, C. A., Talabot‐Ayer, D., & Gabay, C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27235 · Cited by 58
Reimers, J. I., Christensen, U. B., Mandrup-Poulsen, T. R., & Nerup, J. (1994) · Cytokine · doi:10.1016/1043-4666(94)90079-5 · Cited by 57
Self-citationKarlsen, A. E., Pavlović, D., Nielsen, K., Jensen, J. N., Andersen, H. U., Pociot, F., Mandrup-Poulsen, T. R., Eizirik, D. L., & Nerup, J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6366 · Cited by 57
Self-citationWeksler‐Zangen, S., Raz, I., Lenzen, S., Jörns, A., Ehrenfeld, S., Amir, G., Oprescu, A. I., Yagil, Y., Yagil, C., Zangen, D., et al. (2007) · Diabetes · doi:10.2337/db07-0520 · Cited by 54
Mandrup-Poulsen, T. R., Wogensen, L., Jensen, M. C., Svensson, P., Nilsson, P., Emdal, T., Mølvig, J., Dinarello, C. A., & Nerup, J. (1995) · Critical Care Medicine · doi:10.1097/00003246-199501000-00008 · Cited by 48
Self-citationFunctional and morphological effects of interleukin-1? on the perfused rat pancreas
Wogensen, L., Kolb‐Bachofen, V., Christensen, P., Dinarello, C. A., Mandrup-Poulsen, T. R., Martin, S., & Nerup, J. (1990) · Diabetologia · doi:10.1007/bf00586456 · Cited by 34
Self-citationWogensen, L., Reimers, J., Nerup, J., et al. (1992) · Diabetologia · doi:10.1007/bf00401200 · Cited by 26
Cited by
Inflammatory responses and inflammation-associated diseases in organs
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,143
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationInflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
Senescence and aging: Causes, consequences, and therapeutic avenues
McHugh, D., & Gil, J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708092 · Cited by 1,233
Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A. I., Martínez, C. M., Amores-Iniesta, J., Compan, V., Barberà-Cremades, M., Yagüe, J., Ruiz-Ortiz, E., Antón, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2919 · Cited by 790
Metadata
- Authors
- Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2010-08
- Volume
- 17
- Issue
- 4
- Pages
- 314-321
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W1803405992
- Cited by
- 327
- References
- 46
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.